On Sept. 28, 2020, Immunic announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase 2 CALVID-1 trial of its selective oral DHODH inhibitor, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).

Based on the available safety data, an Independent Data Monitoring Committee concluded that the study should continue without changes. To date, 110 patients had been enrolled in the CALVID-1 trial.